Literature DB >> 23242984

Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.

Servet Bölükbas1, Michael Eberlein, Natalie Kudelin, Melanie Demes, Sonja Stallmann, Annette Fisseler-Eckhoff, Joachim Schirren.   

Abstract

OBJECTIVES: The role of radical pleurectomy (RP) in the management of IMIG stage III in malignant pleural mesothelioma (MPM) remains controversial. The aim of the study was to investigate the feasibility and outcome as well as to determine factors predicting poor survival.
METHODS: Patients having IMIG stage III MPM were identified within a prospective multimodality treatment study (RP followed by chemoradiation) between 2002 and 2010 at a single institution. Kaplan-Meier analyses, log-rank test and Cox regression analyses were used to estimate survival and to determine predictors of survival.
RESULTS: A total of 78 patients (66.3 ± 2.5 years, 65 males) underwent RP followed by chemoradiation. A total of 42 (54%) had IMIG stage III. Mortality and morbidity were 4.8 and 31%, respectively. Median survival and 5-year survival were 21 months and 28%, respectively, for stage III patients. Progression-free survival was 11 months. The sites of failure were predominantly locoregional (20/42, 47.6%). Pathological detection of tumour spread at the resected thoracoscopy incisions (median survival 12 vs 35 months, P < 0.001), incomplete resections (median survival 13 vs 35 months, P = 0.01) and male gender (median survival 18 vs 68 months, P < 0.039) were associated with inferior survival in the univariate analyses. Histology, lymph node metastases, laterality and age had no significant impact on survival. The tumour spread at the resected previous incisions remained the only significant prognostic factor (hazard ratio (HR) = 4.3; P = 0.027) in the multivariate analysis. Patients having tumour spread had survival comparable to that of patients at stage IV in the complete patient cohort (median survival 12 vs 8 months; P = 0.39).
CONCLUSIONS: Lung-sparing RP for IMIG stage III MPM is feasible and offers promising long-term survival. The tumour spread at the resected previous incisions is associated with more incomplete resections and was a negative prognosticator for long-term survival. The tumour spread at the resected previous incisions or chest tube sites should be considered as T4 or stage IV according to the IMIG staging system.

Entities:  

Keywords:  IMIG; Malignant pleural mesothelioma; Pleurectomy; Staging; Surgery

Mesh:

Year:  2012        PMID: 23242984     DOI: 10.1093/ejcts/ezs648

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.

Authors:  Koji Kawaguchi; Tetsuo Taniguchi; Noriyasu Usami; Takayuki Fukui; Futoshi Ishiguro; Shota Nakamura; Kohei Yokoi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-11-27

Review 2.  Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).

Authors:  Hasan Fevzi Batirel
Journal:  Ann Transl Med       Date:  2017-06

3.  A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.

Authors:  Shuai Wang; Ke Ma; Zongwei Chen; Xiaodong Yang; Fenghao Sun; Yulin Jin; Yu Shi; Wei Jiang; Qun Wang; Cheng Zhan
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

4.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.

Authors:  Robert Ryan Meyerhoff; Chi-Fu Jeffrey Yang; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry
Journal:  J Surg Res       Date:  2015-01-29       Impact factor: 2.192

5.  Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients.

Authors:  Arnulf Holzknecht; Oliver Illini; Maximilian J Hochmair; Dagmar Krenbek; Ulrike Setinek; Florian Huemer; Erwin Bitterlich; Christoph Kaindl; Vladyslav Getman; Ahmet Akan; Michael Weber; Gunther Leobacher; Arschang Valipour; Michael R Mueller; Stefan B Watzka
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 6.  [Surgical aspects of malignant pleural mesothelioma: from the perspective of pathology].

Authors:  A Fisseler-Eckhoff
Journal:  Chirurg       Date:  2013-06       Impact factor: 0.955

Review 7.  Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.

Authors:  Seiki Hasegawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-03-19

Review 8.  Malignant mesothelioma as a difficult interdisciplinary problem.

Authors:  Wojciech Rokicki; Marek Rokicki; Jacek Wojtacha; Mateusz K Rydel
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-12-20

9.  Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma.

Authors:  Giuseppe Mangiameli; Edoardo Bottoni; Umberto Cariboni; Giorgio Maria Ferraroli; Emanuela Morenghi; Veronica Maria Giudici; Emanuele Voulaz; Marco Alloisio; Alberto Testori
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.